TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04784468

Intervention type: OTHER
Intervention: No intervention
Description: Case-control design, one single investigation

Intervention type: OTHER
Intervention: No intervention
Description: Case-control design, one single investigation
Study: NCT02528682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MiHA-loaded PD-L-silenced DC Vaccination
Description: Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
Study: NCT05740865

Intervention type: PROCEDURE
Intervention: open posterior instrumented thoracolumbar surgery
Description: Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers

Intervention type: PROCEDURE
Intervention: open posterior instrumented thoracolumbar surgery
Description: Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
Study: NCT01204762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegIFN
Description: Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegIFNα-2a
Description: Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN lambda
Description: Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
Study: NCT04678791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
Study: NCT01616173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8mg/2mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2mL
Study: NCT00166504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: simvastatin/ezetimibe 10/20 mg
Study: NCT04678791

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External-beam radiation
Description: Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiation
Description: Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
Study: NCT03574402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avitinib Maleate
Description: 300mg orally (PO) twice daily (BID) on day 1-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avitinib Maleate
Description: 300mg orally (PO) twice daily (BID) on day 1-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40mg orally once a day, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250mg PO QD on days 1-28. 28 days as one cycle.
Study: NCT04205058

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard coffee
Description: One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine-free coffee
Description: One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Drinking water
Description: One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
Study: NCT00079430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intraperitoneally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT01598194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle
Description: Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
Study: NCT04568057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIR Transcranial phototherapy device
Description: 1068 nm NIR helmet

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcranial Device
Description: The placebo device looks like the active device.
Study: NCT01103687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 (rAd26)
Description: 5 x 10\^10 virus particles (VP) vaccine delivered intramuscularly (IM)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine delivered IM
Study: NCT03574402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396
Description: 225mg PO QD on days 1-28. 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396
Description: 225mg PO QD on days 1-28. 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396
Description: 225mg PO QD on days 1-28. 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg orally twice weekly, 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: 400mg PO QD on days 1-28. 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3759
Description: 200mg PO BID on days 1-28. 28 days as one cycle.
Study: NCT01427608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline + Olanzapine
Description: Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline + Placebo
Description: Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
Study: NCT05697523

Intervention type: OTHER
Intervention: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
Description: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test

Intervention type: OTHER
Intervention: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
Description: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
Study: NCT01806571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT03574402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirotinib
Description: 60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirotinib
Description: 60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
Study: NCT00003799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT03620474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: twice a week for 4 hours continuous intravenous administration of PRI-724
Study: NCT02798016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma
Description: This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-needling
Description: Micro-needling will be applied on the acne scars in one side of the face.
Study: NCT02032004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Precursor Cells (MPCs)
Description: Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
Study: NCT01958346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lingual Traction
Description: The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Standard of care fiberoptic intubation without any additional experimental maneuvers
Study: NCT03574402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg, iv gtt. on day 1,8,15. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg, iv gtt. on day 1,8,15. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
Study: NCT00003799

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT03574402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg iv gtt. Q3W on day1. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg iv gtt. Q3W on day1. 21 days as one cycle.
Study: NCT01958346

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fiberoptic Intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberoptic Intubation
Study: NCT03072706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corin OPS™
Description: The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D X-ray templating technology
Description: Standard care where hip replacement is planned using 2D X-ray templating software
Study: NCT00391066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCR + Lumiliximab
Description: Dose, schedule, and duration specified in the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCR
Description: Dose, schedule, and duration specified in protocol
Study: NCT01806571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03574402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg iv gtt. Q3W on day1. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg iv gtt. Q3W on day1. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg iv gtt. Q3W on day1. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 iv gtt. Q3W on day1. 21 days as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
Study: NCT03599479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Description: Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
Study: NCT01150968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End of life education
Description: Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
Study: NCT00166504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 10 mg
Study: NCT00100542

Intervention type: BEHAVIORAL
Intervention: Psychiatric interviews
Description: Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
Study: NCT04382209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous meperidine patient controlled analgesia device
Description: Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
Study: NCT01343940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project dulce
Description: Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety intervention
Description: Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
Study: NCT01716585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT04303299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral
Description: Anti virus treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral
Description: Anti virus treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral
Description: Anti virus treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral
Description: Anti virus treatment
Study: NCT00003799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study: NCT00262509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Egress Badge
Description: Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
Study: NCT00780325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649 (2 mg)
Description: CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649 (8 mg)
Description: CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
Study: NCT00037921

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bacterial colonization
Study: NCT04988347

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Spirulina platensis
Description: Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
Study: NCT01228357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI treated group
Description: Antidepressant administration of SSRI class for 12 weeks under therapeutic dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-SSRI treated group
Description: Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
Study: NCT02130661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilapladib 25 mg
Description: White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilapladib 250 mg
Description: White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
Study: NCT00300950

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GI-4000
Description: Heat-killed yeast cell transfected with target ras mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy
Study: NCT01806571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03848494

Intervention type: PROCEDURE
Intervention: Surgery
Description: Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
Study: NCT01232933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPS System
Description: Use of the navigational VPS system during catheter placement
Study: NCT03051074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floating
Description: Floating supine in a pool saturated with Epsom salt for up to 90 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Watching a relaxing film for up to 90 minutes